Cargando…
Immunologic Gene Signature Analysis Correlates Myeloid Cells and M2 Macrophages with Time to Trabectedin Failure in Sarcoma Patients
SIMPLE SUMMARY: Trabectedin is an FDA-approved chemotherapy with demonstrated benefit for some sarcoma subtypes, particularly in the metastatic setting. Although some patients receiving trabectedin have only modest benefit, other patients are exceptional responders. While several mechanisms of actio...
Autores principales: | Schroeder, Brett A., Zhang, Yuzheng, Smythe, Kimberly S., Desai, Parth, Thomas, Anish, Viveiros, Pedro, Alexiev, Borislav A., Obeidin, Farres, Chen, Eleanor Y., Cranmer, Lee D., Wagner, Michael J., Jones, Robin L., Campbell, Jean S., Pierce, Robert H., He, Qianchuan, Pollack, Seth M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909887/ https://www.ncbi.nlm.nih.gov/pubmed/35267598 http://dx.doi.org/10.3390/cancers14051290 |
Ejemplares similares
-
Inflammatory leiomyosarcoma/rhabdomyoblastic tumor: A report of two cases with novel genetic findings
por: Sukhanova, Madina, et al.
Publicado: (2022) -
Trabectedin in Soft Tissue Sarcomas
por: Petek, Bradley J., et al.
Publicado: (2015) -
Trabectedin for soft tissue sarcoma
Publicado: (2021) -
What’s new in bone and soft tissue pathology 2023: guidelines for molecular testing
por: Obeidin, Farres
Publicado: (2023) -
The Role of Trabectedin in Soft Tissue Sarcoma
por: Nakamura, Tomoki, et al.
Publicado: (2022)